StockMirror — Stock Screener

ZYDUSLIFE Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Zydus Lifesciences reported strong Q2 FY27 results with consolidated revenue up 29% YoY to ₹79.1 billion and EBITDA margin at 24%. All business segments delivered double-digit growth: India branded formulations +19%, International formulations +33%, US +21%, Consumer wellness +76%. EBITDA at ₹18.9 billion and net profit at ₹9.3 billion. Key developments include Saroglitazar US launch expected March 2027, Keytruda biosimilar BLA accepted for review, and continued specialty transformation with specialty products at 16% of US revenues. Net debt reduced from ₹5900 crores to ₹5200 crores with net debt/EBITDA at 0.62x. Management maintains 24%+ EBITDA margin guidance for FY27 despite increased Saroglitazar investments.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management maintains 24%+ EBITDA margin guidance for FY27 while investing in growth initiatives including Saroglitazar commercialization, R&D for differentiated pipeline, and geographical expansion. Confident in maintaining margins despite investments.

About Zydus Lifesciences Limited

Zydus Lifesciences Limited (ZYDUSLIFE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More